Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ikaria receives Class I notice for drug delivery system recall

This article was originally published in Clinica

Executive Summary

Biotherapeutics firm Ikaria has been given a Class I notification from the US FDA after it recalled its Inomax DS drug delivery system. During ongoing review processes the firm discovered that a component within the pressure switch of the system is prone to tearing. This could cause worsening of low blood oxygen, low blood pressure and/or an increase in pulmonary arterial pressure, and death. The company informed customers of the fault on 21 July. The recall affects products distributed from 20 August 2007 to 15 July 2010 and is in effect in the US and Canada. The Clinton, New Jersey-based firm has begun to replace the systems. The Inomax DS system is designed to deliver nitric oxide to patients to help them breathe.

You may also be interested in...

Alere aided by professional diagnostics sales in fourth quarter

Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.

Integra and Stout to work on expandable interbody device

Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.

Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials

Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts